Vincent Aroulmoji
Research Interests
Vincent Aroulmoji has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
- Ponnusamy Munusamy Anbarasan
Department of Physics, Periyar University, Salem, India
12 shared publications K. Prabakaran
9 shared publicationsRiaz Khan
Department of Chemistry, Rumsey, Sonning
7 shared publicationsErminio Murano
Istituto di Ricerca Protos, Via Flavia 23/1, c/o BIC Incubatori FVG, 34148, Trieste, Italy
5 shared publicationsFrancesca Dinon
Cimteclab Spa, c/o Area Science Park, Padriciano 99, Trieste, 34149, Italy
5 shared publications- Gopal Rajarajan
Vidhya Mandhir Institute of Technology
5 shared publications
Latest Publications
- 27 March 2024
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 43 (16) , 9059-9073
In silico validation of hyaluronic acid – drug conjugates based targeted drug delivery for the treatment of COVID-19
The impact of COVID-19 urges scientists to develop targeted drug delivery to manage Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viral infections with a fast recovery rate. The aim of the study is to develop Hyaluronic Acid (HA) drug conjugates of viral drugs to target two important enzymes (Mpro and PLpro) of SARS-CoV-2. Three antiviral drugs, namely Dexamethasone (DEX), Favipiravir (FAV), and Remdesivir (REM), were chosen for HA conjugation due to their reactive functional groups. Free forms of drugs (DEX, FAV, REM) and HA drug conjugates (HA-DEX, HA-FAV, HA-REM, HA-RHA, HA-RHE) were validated against Mpro (PDB ID 6LU7) and PLpro (PDB 7LLZ), which play an essential role in the replication and reproduction of the SARS-CoV-2 virus. The results of the present study revealed that HA-drug conjugates possess higher binding affinity and the best docking score towards the Mpro and PLpro target proteins of SARS-CoV-2 than their free forms of drugs. ADMET screening resulted that HA-drug conjugates exhibited better pharmacokinetic profiles than their pure forms of drugs. Further, molecular dynamic simulation studies, essential dynamics and free energy landscape analyses show that HA antiviral drug conjugates possess good trajectories and energy status, with the PLpro target protein (PDB 7LLZ) of SARS-CoV-2 through long-distance (500 ns) simulation screening. The research work recorded the best drug candidate for Cell-Targeted Drug Delivery (CTDD) for SARS-CoV-2-infected cells through hyaluronic acid conjugates of antiviral drugs.Communicated by Ramaswamy H. Sarma.
- 27 March 2024
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 43 (16) , 9059-9073
In silico validation of hyaluronic acid – drug conjugates based targeted drug delivery for the treatment of COVID-19
The impact of COVID-19 urges scientists to develop targeted drug delivery to manage Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viral infections with a fast recovery rate. The aim of the study is to develop Hyaluronic Acid (HA) drug conjugates of viral drugs to target two important enzymes (Mpro and PLpro) of SARS-CoV-2. Three antiviral drugs, namely Dexamethasone (DEX), Favipiravir (FAV), and Remdesivir (REM), were chosen for HA conjugation due to their reactive functional groups. Free forms of drugs (DEX, FAV, REM) and HA drug conjugates (HA-DEX, HA-FAV, HA-REM, HA-RHA, HA-RHE) were validated against Mpro (PDB ID 6LU7) and PLpro (PDB 7LLZ), which play an essential role in the replication and reproduction of the SARS-CoV-2 virus. The results of the present study revealed that HA-drug conjugates possess higher binding affinity and the best docking score towards the Mpro and PLpro target proteins of SARS-CoV-2 than their free forms of drugs. ADMET screening resulted that HA-drug conjugates exhibited better pharmacokinetic profiles than their pure forms of drugs. Further, molecular dynamic simulation studies, essential dynamics and free energy landscape analyses show that HA antiviral drug conjugates possess good trajectories and energy status, with the PLpro target protein (PDB 7LLZ) of SARS-CoV-2 through long-distance (500 ns) simulation screening. The research work recorded the best drug candidate for Cell-Targeted Drug Delivery (CTDD) for SARS-CoV-2-infected cells through hyaluronic acid conjugates of antiviral drugs.Communicated by Ramaswamy H. Sarma.
- 12 January 2024
- Published by Elsevier in Sustainable Energy Technologies and Assessments
- Vol. 62
A concise review of recent biohydrogen production technologies
- 12 January 2024
- Published by Elsevier in Sustainable Energy Technologies and Assessments
- Vol. 62
A concise review of recent biohydrogen production technologies
- 16 March 2022
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 41 (8) , 3562-3573
Molecular insights of hyaluronic acid – ethambutol and hyaluronic acid – isoniazid drug conjugates act as promising novel drugs for the treatment of tuberculosis
The present study examines cellular targeted drug delivery (CTDD) pattern of two novel Hyaluronic acid (HA) Tuberculosis Drug (TB) conjugates and its efficacy and strong binding affinity towards TB molecular protein targets. Two TB drugs ethambutol (EB) and isoniazid (IN) and their Hyaluronic acid conjugates (HA-EB & HA-IN) were tested for its metabolism, toxicity and excretion prediction through In silico tools they revealed hyaluronic acid conjugate of two TB drugs exhibited good drug profile over their free form of TB drugs. Further these four molecules subjected to In silico molecular docking study with four potential Mycobacterium tuberculosis target proteins (3PD8, 4Y0L, 5DZK and 6GAU). Molecular docking study revealed that hyaluronic conjugates (HA-EB & HA-IN) exhibit significant binding affinity and excellent docking scores with all screened molecular protein targets of TB over their free form of drug. Further molecular dynamic simulation was calculated for the four drug molecules (EB, IN, HA- EB & HA-IN) with DNA gyrase enzyme (PDB ID 6GAU) of Mycobacterium tuberculosis and the MDS results revealed that both the conjugates with the TB target protein possessed good number of interaction with binding pocket residues and good simulation scores than the free form of drugs. Communicated by Ramaswamy H. Sarma
- 16 March 2022
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 41 (8) , 3562-3573
Molecular insights of hyaluronic acid – ethambutol and hyaluronic acid – isoniazid drug conjugates act as promising novel drugs for the treatment of tuberculosis
The present study examines cellular targeted drug delivery (CTDD) pattern of two novel Hyaluronic acid (HA) Tuberculosis Drug (TB) conjugates and its efficacy and strong binding affinity towards TB molecular protein targets. Two TB drugs ethambutol (EB) and isoniazid (IN) and their Hyaluronic acid conjugates (HA-EB & HA-IN) were tested for its metabolism, toxicity and excretion prediction through In silico tools they revealed hyaluronic acid conjugate of two TB drugs exhibited good drug profile over their free form of TB drugs. Further these four molecules subjected to In silico molecular docking study with four potential Mycobacterium tuberculosis target proteins (3PD8, 4Y0L, 5DZK and 6GAU). Molecular docking study revealed that hyaluronic conjugates (HA-EB & HA-IN) exhibit significant binding affinity and excellent docking scores with all screened molecular protein targets of TB over their free form of drug. Further molecular dynamic simulation was calculated for the four drug molecules (EB, IN, HA- EB & HA-IN) with DNA gyrase enzyme (PDB ID 6GAU) of Mycobacterium tuberculosis and the MDS results revealed that both the conjugates with the TB target protein possessed good number of interaction with binding pocket residues and good simulation scores than the free form of drugs. Communicated by Ramaswamy H. Sarma
- 1 August 2021
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1238, 130457
Molecular insights of hyaluronic acid-hydroxychloroquine conjugate as a promising drug in targeting SARS-CoV-2 viral proteins
- 1 August 2021
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1238, 130457
Molecular insights of hyaluronic acid-hydroxychloroquine conjugate as a promising drug in targeting SARS-CoV-2 viral proteins
- 26 August 2020
- Published by Springer Nature in Journal of Sol-Gel Science and Technology
- Vol. 96 (2) , 416-422
Sol–Gel synthesis of Co3O4 nanoparticles as an electrode material for supercapacitor applications
- 26 August 2020
- Published by Springer Nature in Journal of Sol-Gel Science and Technology
- Vol. 96 (2) , 416-422
Sol–Gel synthesis of Co3O4 nanoparticles as an electrode material for supercapacitor applications
- 25 August 2020
- Published by Mahendra Publications in International Journal of Advanced Science and Engineering
- Vol. 7 (1)
Hyaluronic Acid – TB Drug Conjugates for the Treatment of Active Tuberculosis Disease
- 25 August 2020
- Published by Mahendra Publications in International Journal of Advanced Science and Engineering
- Vol. 7 (1)
Hyaluronic Acid – TB Drug Conjugates for the Treatment of Active Tuberculosis Disease
- 29 June 2020
- Published by Springer Nature in International Journal of Peptide Research and Therapeutics
- Vol. 27 (1) , 385-395
Isolation, Characterization and In-Silico Study of Conotoxin Protein from Conus loroisii and Its Anti-cancer Activity
- 29 June 2020
- Published by Springer Nature in International Journal of Peptide Research and Therapeutics
- Vol. 27 (1) , 385-395
Isolation, Characterization and In-Silico Study of Conotoxin Protein from Conus loroisii and Its Anti-cancer Activity
- 27 March 2020
- Published by Mahendra Publications in International Journal of Advanced Science and Engineering
- Vol. 6 (4)
Focal Hole Shifting of Azimuthally Polarized Sinh Gaussian Beam using Cosine Phase Filter
- 27 March 2020
- Published by Mahendra Publications in International Journal of Advanced Science and Engineering
- Vol. 6 (4)
Focal Hole Shifting of Azimuthally Polarized Sinh Gaussian Beam using Cosine Phase Filter
- 27 March 2020
- Published by Mahendra Publications in International Journal of Advanced Science and Engineering
- Vol. 06 (04)
Hyaluronic Acid - Hydroxychloroquine Conjugate Proposed for Treatment of COVID-19
- 27 March 2020
- Published by Mahendra Publications in International Journal of Advanced Science and Engineering
- Vol. 06 (04)
Hyaluronic Acid - Hydroxychloroquine Conjugate Proposed for Treatment of COVID-19